JBIO PE Ratio & Valuation,Is JBIO Overvalued

JBIO Relative Valuation

JBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, JBIO is overvalued; if below, it's undervalued.

Historical Valuation

Jade Biosciences Inc (JBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.09. The fair price of Jade Biosciences Inc (JBIO) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：15.25

Fair

-5.06

0.00

EV/EBITDA

Jade Biosciences Inc. (JBIO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-4.85

EV/EBIT

Jade Biosciences Inc. (JBIO) has a current EV/EBIT of -4.85. The 5-year average EV/EBIT is -2.63. The thresholds are as follows: Strongly Undervalued below -6.34, Undervalued between -6.34 and -4.49, Fairly Valued between -0.78 and -4.49, Overvalued between -0.78 and 1.07, and Strongly Overvalued above 1.07. The current Forward EV/EBIT of -4.85 falls within the Undervalued range.

0.00

Jade Biosciences Inc. (JBIO) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-6.42

P/OCF

Jade Biosciences Inc. (JBIO) has a current P/OCF of -6.42. The 5-year average P/OCF is -4.20. The thresholds are as follows: Strongly Undervalued below -7.85, Undervalued between -7.85 and -6.03, Fairly Valued between -2.38 and -6.03, Overvalued between -2.38 and -0.55, and Strongly Overvalued above -0.55. The current Forward P/OCF of -6.42 falls within the Undervalued range.

-6.59

P/FCF

Jade Biosciences Inc. (JBIO) has a current P/FCF of -6.59. The 5-year average P/FCF is -3.58. The thresholds are as follows: Strongly Undervalued below -5.86, Undervalued between -5.86 and -4.72, Fairly Valued between -2.44 and -4.72, Overvalued between -2.44 and -1.31, and Strongly Overvalued above -1.31. The current Forward P/FCF of -6.59 falls within the Strongly Undervalued range.

Jade Biosciences Inc (JBIO) has a current Price-to-Book (P/B) ratio of -1.86. Compared to its 3-year average P/B ratio of -1.13 , the current P/B ratio is approximately 64.30% higher. Relative to its 5-year average P/B ratio of -1.13, the current P/B ratio is about 64.30% higher. Jade Biosciences Inc (JBIO) has a Forward Free Cash Flow (FCF) yield of approximately -6.56%. Compared to its 3-year average FCF yield of -15.43%, the current FCF yield is approximately -57.47% lower. Relative to its 5-year average FCF yield of -15.43% , the current FCF yield is about -57.47% lower.

-1.86

P/B

Median3y

-1.13

Median5y

-1.13

-6.56

FCF Yield

Median3y

-15.43

Median5y

-15.43

Competitors Valuation Multiple

The average P/S ratio for JBIO's competitors is -446.35, providing a benchmark for relative valuation. Jade Biosciences Inc Corp (JBIO) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of JBIO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of JBIO in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Jade Biosciences Inc (JBIO) currently overvalued or undervalued?

What is Jade Biosciences Inc (JBIO) fair value?

JBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Jade Biosciences Inc (JBIO) is between to according to relative valuation methord.

How does JBIO's valuation metrics compare to the industry average?

The average P/S ratio for JBIO's competitors is -446.35, providing a benchmark for relative valuation. Jade Biosciences Inc Corp (JBIO) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Jade Biosciences Inc (JBIO) as of Dec 15 2025?

As of Dec 15 2025, Jade Biosciences Inc (JBIO) has a P/B ratio of -1.86. This indicates that the market values JBIO at -1.86 times its book value.

What is the current FCF Yield for Jade Biosciences Inc (JBIO) as of Dec 15 2025?

As of Dec 15 2025, Jade Biosciences Inc (JBIO) has a FCF Yield of -6.56%. This means that for every dollar of Jade Biosciences Inc’s market capitalization, the company generates -6.56 cents in free cash flow.

What is the current Forward P/E ratio for Jade Biosciences Inc (JBIO) as of Dec 15 2025?

As of Dec 15 2025, Jade Biosciences Inc (JBIO) has a Forward P/E ratio of -5.06. This means the market is willing to pay $-5.06 for every dollar of Jade Biosciences Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Jade Biosciences Inc (JBIO) as of Dec 15 2025?

As of Dec 15 2025, Jade Biosciences Inc (JBIO) has a Forward P/S ratio of 0.00. This means the market is valuing JBIO at $0.00 for every dollar of expected revenue over the next 12 months.

JBIO Valuation